CA2462200A1 - Peptidomimetics of biologically active metallopeptides - Google Patents

Peptidomimetics of biologically active metallopeptides Download PDF

Info

Publication number
CA2462200A1
CA2462200A1 CA002462200A CA2462200A CA2462200A1 CA 2462200 A1 CA2462200 A1 CA 2462200A1 CA 002462200 A CA002462200 A CA 002462200A CA 2462200 A CA2462200 A CA 2462200A CA 2462200 A1 CA2462200 A1 CA 2462200A1
Authority
CA
Canada
Prior art keywords
amino acid
peptidomimetic
phe
metallopeptide
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462200A
Other languages
English (en)
French (fr)
Inventor
Shubh D. Sharma
Yiqun Shi
Ramesh Rajpurohit
Zhijun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462200A1 publication Critical patent/CA2462200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
CA002462200A 2001-08-10 2002-08-12 Peptidomimetics of biologically active metallopeptides Abandoned CA2462200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31140401P 2001-08-10 2001-08-10
US60/311,404 2001-08-10
PCT/US2002/025574 WO2003013571A1 (en) 2001-08-10 2002-08-12 Peptidomimetics of biologically active metallopeptides

Publications (1)

Publication Number Publication Date
CA2462200A1 true CA2462200A1 (en) 2003-02-20

Family

ID=23206723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462200A Abandoned CA2462200A1 (en) 2001-08-10 2002-08-12 Peptidomimetics of biologically active metallopeptides

Country Status (6)

Country Link
US (4) US7326707B2 (US07807678-20101005-C00128.png)
EP (1) EP1425029A4 (US07807678-20101005-C00128.png)
JP (1) JP2005504043A (US07807678-20101005-C00128.png)
AU (1) AU2002331064B2 (US07807678-20101005-C00128.png)
CA (1) CA2462200A1 (US07807678-20101005-C00128.png)
WO (1) WO2003013571A1 (US07807678-20101005-C00128.png)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
EP1469875A1 (en) * 2002-01-29 2004-10-27 Wyeth Compositions and methods for modulating connexin hemichannels
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
WO2005102340A1 (en) * 2003-05-30 2005-11-03 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
WO2005079574A1 (en) * 2004-01-21 2005-09-01 Palatin Technologies, Inc. Bicyclic melanocorin-specific compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
ATE460159T1 (de) 2005-01-26 2010-03-15 Allergan Inc Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino- propylaminen, 3-benzyl-3 hydroxy-2-amino- propionsäureamiden und verwandten verbindungen als analgetika
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
SG170767A1 (en) 2005-12-23 2011-05-30 Zealand Pharma As Modified lysine-mimetic compounds
KR101069051B1 (ko) 2006-05-23 2011-09-29 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
PT2104535E (pt) * 2007-01-10 2011-03-31 Irm Llc Compostos e composições como inibidores da protease de activação de canal
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
US20090081197A1 (en) * 2007-06-01 2009-03-26 Palatin Technologies, Inc. Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity
US20090076029A1 (en) * 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2257533B1 (en) * 2008-02-29 2013-09-18 Mimetica Pty Limited 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8008291B2 (en) 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011156246A1 (en) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
CA2815855C (en) 2010-11-01 2016-02-02 Rfs Pharma, Llc Novel specific hcv ns3 protease inhibitors
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
MX339762B (es) * 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106689A1 (en) 2012-01-12 2013-07-18 Ref Pharma, Llc. Hcv ns3 protease inhibitors
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
CN110981936B (zh) * 2018-09-28 2021-10-12 北京京东方技术开发有限公司 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148923A (en) 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US4626549A (en) 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
IT1157365B (it) 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4711957A (en) 1979-07-13 1987-12-08 The B. F. Goodrich Company Synthesis of 2-keto-1,4-diazacycloalkanes
US4434454A (en) * 1981-02-06 1984-02-28 Day J Michael Active lighting system including light control keyboard
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
US4968684A (en) 1987-04-01 1990-11-06 Janssen Pharmaceutica N.V. Method of improving sleep
KR900018073A (ko) * 1988-05-23 1990-12-20 추후보충 피페라진 화합물
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5120713A (en) 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
SE9202266D0 (sv) 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
US5432691A (en) * 1992-11-18 1995-07-11 Vari-Lite, Inc. Automated truss module with deployment mechanism
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
WO1994021608A1 (en) 1993-03-25 1994-09-29 The Upjohn Company Indoletetralins having dopaminergic activity
HUT70045A (en) 1993-06-17 1995-09-28 Takeda Chemical Industries Ltd 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them
US5736539A (en) * 1993-06-18 1998-04-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5599809A (en) * 1994-09-29 1997-02-04 Merck & Co., Inc. Method for improving reproductive efficiency in farm animals
US6245764B1 (en) * 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69633442T2 (de) 1995-04-13 2006-01-05 Aventis Pharmaceuticals Inc. Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung
AU5514296A (en) * 1995-04-26 1996-11-18 Takeda Chemical Industries Ltd. Piperazinones useful as inhibitors of platelet aggregation
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
DE19518988A1 (de) 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
ATE288444T1 (de) 1995-05-29 2005-02-15 Pfizer Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6087357A (en) * 1995-12-18 2000-07-11 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as tachykinin antagonists
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
GB9612276D0 (en) 1996-06-12 1996-08-14 Merck & Co Inc 4-Spiroindoline piperidines promote release of growth hormone
US5804578A (en) 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
GB9611461D0 (en) * 1996-06-01 1996-08-07 Ciba Geigy Ag New compounds
US6331285B1 (en) 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
EP0852117A4 (en) 1996-06-12 1999-02-03 Kyowa Hakko Kogyo Kk IMPROVEMENT OF LIPID METABOLISM
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
WO1998017625A1 (fr) * 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Nouveaux remedes pour des maladies infectieuses
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
US5965565A (en) 1996-12-12 1999-10-12 Merck & Co., Inc. Piperidines promote release of growth hormone
US6333324B1 (en) 1996-12-17 2001-12-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of MMP or TNF
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
JP2001523245A (ja) 1997-04-24 2001-11-20 メルク シヤープ エンド ドーム リミテツド 肥満を治療するためのｎｋ−１受容体拮抗薬およびｓｓｒｉの使用
DE69825995T2 (de) 1997-05-27 2005-09-08 Direct-Haler A/S Inhalator für pulverförmige medikamente
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US5968938A (en) 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
US6287587B2 (en) * 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6211626B1 (en) * 1997-08-26 2001-04-03 Color Kinetics, Incorporated Illumination components
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US5892038A (en) * 1997-12-08 1999-04-06 Pharmacopeia, Inc. Hydroxy-amino acid amides
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
US6613234B2 (en) * 1998-04-06 2003-09-02 Ciphergen Biosystems, Inc. Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography
WO1999055679A1 (en) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
US6140354A (en) 1998-04-29 2000-10-31 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
CA2329881C (en) 1998-05-11 2010-03-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO1999064002A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
BRPI9911756B1 (pt) * 1998-06-30 2016-06-14 Helsinn Healthcare Sa composto, uso do mesmo, e composição farmaceutica
FR2780649B1 (fr) * 1998-07-06 2001-03-09 Univ Paris Vii Denis Diderot Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
CA2335378A1 (en) 1998-07-21 2000-02-03 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
BR9912944A (pt) 1998-08-12 2001-05-08 Pfizer Prod Inc Inibidores de tace
WO2000017348A1 (en) * 1998-09-17 2000-03-30 Hopital Sainte-Justine G protein-coupled receptor agonists or antagonists
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6800636B2 (en) * 1998-12-18 2004-10-05 Schering Corporation Farnesyl protein transferase inhibitors
US6372747B1 (en) * 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
US6294539B1 (en) 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6715485B1 (en) * 1999-03-03 2004-04-06 Optinose As Nasal delivery device
US6033656A (en) 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
AU6605800A (en) 1999-07-16 2001-02-05 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP2004519410A (ja) * 1999-08-12 2004-07-02 パラチン テクノロジーズ インク． メラノコルチンメタロペプチド構成体、無作為配列ライブラリー及び適用法
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9921239D0 (en) 1999-09-08 1999-11-10 Plant Bioscience Ltd Plant resistance gene
CN1560249A (zh) 1999-09-08 2005-01-05 杰南技术公司 成纤维细胞生长因子-19（fgf-19）的核酸和多肽以及用于治疗肥胖的方法
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
EP1214351A2 (en) 1999-09-22 2002-06-19 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6515122B1 (en) 1999-09-24 2003-02-04 Lion Bioscience Ag Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
JP2003525217A (ja) 1999-10-22 2003-08-26 メルク エンド カムパニー インコーポレーテッド 肥満治療用薬剤
WO2001030808A1 (en) * 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) * 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
JP2001184828A (ja) * 1999-12-21 2001-07-06 Sony Corp ライナ貼付方法及びライナ貼付装置
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE19963234A1 (de) 1999-12-27 2002-01-24 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6462046B2 (en) * 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
US6693165B2 (en) * 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
EP1125579A3 (en) 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
WO2001055107A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
WO2001055106A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001070347A1 (en) 2000-03-17 2001-09-27 Fit Express, Inc. Golf swing conditioner
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
US6472398B1 (en) 2000-03-23 2002-10-29 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
CN1450999A (zh) * 2000-03-31 2003-10-22 辉瑞产品公司 新的哌嗪衍生物
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
SK18322002A3 (sk) 2000-06-27 2003-09-11 Taisho Pharmaceutical Co., Ltd. Terapeutický prostriedok proti úzkosti alebo depresii a piperazínové deriváty
AU2001260548A1 (en) 2000-06-28 2002-01-08 Pfizer Products Inc. Melanocortin receptor ligands
CA2414198A1 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
PT1315750E (pt) 2000-08-30 2007-05-31 Hoffmann La Roche Péptidos cíclicos com actividade agonista para o receptor 4 de melanocortina
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
KR100394083B1 (ko) * 2000-12-04 2003-08-06 학교법인 성신학원 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법
US6612805B2 (en) 2000-12-05 2003-09-02 Emu Unterwasserpumpen Gmbh Hydrodynamic machine
CN1496254A (zh) 2000-12-15 2004-05-12 ������ҩ�����޹�˾ 男性性功能障碍的治疗
DE60205465T2 (de) 2001-01-23 2006-04-20 Eli Lilly And Co., Indianapolis Piperazinderivate als agonisten des melanocortin-rezeptors
AU2002250343B2 (en) 2001-02-28 2006-05-25 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068387A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
JP2005506286A (ja) 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリック−ａｍｐ関連疾患の治療を目的としたメラノコルチン受容体アゴニストおよびホスホジエステラーゼ阻害剤の併用投与
EP1363631A4 (en) * 2001-03-02 2005-11-16 Bristol Myers Squibb Co "COMPOUNDS SUITED AS MODULATORS OF MELANOCORTIN RECEPTORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF"
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
EP1385823B1 (en) 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
MXPA03010232A (es) 2001-05-11 2004-03-16 Biovitrum Ab Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
BRPI0209821B1 (pt) 2001-05-15 2016-09-27 Hoffmann La Roche composto, processo para a manufatura desse composto, composição farmacêutica que compreende o mesmo e uso do composto
KR20040007565A (ko) * 2001-05-15 2004-01-24 다이쇼 세이야꾸 가부시끼가이샤 아르기닌 유도체
US6593362B2 (en) * 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
BR0210531A (pt) * 2001-06-20 2004-06-22 Pfizer Prod Inc Derivados de ácido sulfÈnico
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
US6969719B2 (en) 2001-08-28 2005-11-29 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
AU2002326948A1 (en) * 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
US20050069883A1 (en) 2001-09-26 2005-03-31 Howard Andrew D. Melanin-concentrating hormone receptor antagonist binding protein
WO2003031410A1 (en) 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
CN1575283A (zh) * 2001-10-22 2005-02-02 辉瑞产品公司 具有ccr1受体拮抗剂活性的哌嗪衍生物
ES2275918T3 (es) 2001-11-08 2007-06-16 Ortho-Mcneil Pharmaceutical, Inc. Derivados del 1,2,4-tiazol novedosos como moduladores de los receptores de la melanocortina.
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
WO2003055477A1 (en) 2001-12-21 2003-07-10 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
PL369076A1 (en) * 2001-12-21 2005-04-18 Taisho Pharmaceutical Co, Ltd. Piperazine derivative
WO2003061660A1 (en) 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
US20030195187A1 (en) 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20030207814A1 (en) 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
WO2003072056A2 (en) 2002-02-25 2003-09-04 Chiron Corporation Intranasal administration of mc4-r agonists
AU2003230367A1 (en) * 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
WO2004078716A1 (en) 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
US7834017B2 (en) * 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US20090076029A1 (en) * 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity

Also Published As

Publication number Publication date
EP1425029A4 (en) 2006-06-07
US20040152134A1 (en) 2004-08-05
US7601753B2 (en) 2009-10-13
JP2005504043A (ja) 2005-02-10
US20070155670A1 (en) 2007-07-05
AU2002331064B2 (en) 2007-08-23
US20040171520A1 (en) 2004-09-02
US7807678B2 (en) 2010-10-05
WO2003013571A1 (en) 2003-02-20
US20040167201A1 (en) 2004-08-26
US7189755B2 (en) 2007-03-13
EP1425029A1 (en) 2004-06-09
US7326707B2 (en) 2008-02-05

Similar Documents

Publication Publication Date Title
AU2002331064B2 (en) Peptidomimetics of biologically active metallopeptides
AU2002331064A1 (en) Peptidomimetics of biologically active metallopeptides
AU2002322466B2 (en) Linear and cyclic melanocortin receptor-specific peptides
SCHILLER Conformational analysis of enkephalin and conformation–activity relationships
CN100384819C (zh) 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
Balboni et al. Potent δ-Opioid Receptor Agonists Containing the Dmt− Tic Pharmacophore
Williams et al. 1-(((7, 7-Dimethyl-2 (S)-(2 (S)-amino-4-(methylsulfonyl) butyramido) bicyclo [2.2. 1] heptan-1 (S)-yl) methyl) sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor
Sun et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics
Rivera et al. A multicomponent conjugation strategy to unique N‐steroidal peptides: first evidence of the steroidal nucleus as a β‐turn inducer in acyclic peptides
AU2004235792A2 (en) Melanocortin receptor-specific compounds
US7354923B2 (en) Piperazine melanocortin-specific compounds
Creighton et al. Design, synthesis, and conformational analysis of eight-membered cyclic peptidomimetics prepared using ring closing metathesis
Mollica et al. New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4, 4′ positions and non-hydrazine linkers
US20080255033A1 (en) Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds
Cain et al. Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors
US20060240481A1 (en) Melanocortin Metallopeptode Combinatorial Libraries and Applications
Bourguet et al. Benzophenone semicarbazone protection strategy for synthesis of aza‐glycine containing aza‐peptides
CA2379647A1 (en) Melanocortin metallopeptide constructs, combinatorial libraries and applications
Lee et al. Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at μ and δ opioid receptors
Mollica et al. Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers
Zask et al. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents
Bańkowski et al. N‐terminal guanidinylation of the cyclic 1, 4‐ureido‐deltorphin analogues: the synthesis, receptor binding studies, and resistance to proteolytic digestion
Fry et al. Utilizing peptide structures as keys for unlocking challenging targets
WO2005102340A1 (en) Piperazine melanocortin-specific compounds
ZA200509683B (en) Melanocortin receptor-specific compounds

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20110812

FZDE Discontinued

Effective date: 20110812